secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001628280-23-007139
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn reports FY2022 net loss $108.9M; cash $345.8M; pipeline data expected H1 2023
--------------------------------------------------------------------------------

- Net loss $108.9M for FY2022; R&D expenses $105.6M, collaboration revenue $19.2M.
- Cash, equivalents and marketable securities $345.8M as of Dec 31, 2022; runway into H2 2025.
- Phase 1 data for FHD-286 in mUM expected H1 2023; AML/MDS clinical hold update H1 2023.
- Phase 1 data for FHD-609 in synovial sarcoma expected mid-2023.
- Newly disclosed selective EP300 degrader targeting CBP mutant cancers; potential for >100K patients/year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023007139/0001628280-23-007139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023007139/fhtx-20230307.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-007139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer